

Interview Summary	Application No.	Applicant(s)	
	09/194,356	NERI ET AL.	
	Examiner	Art Unit	
	Alana M. Harris, Ph.D.	1643	

All participants (applicant, applicant's representative, PTO personnel):

(1) Alana M. Harris, Ph.D.

(3) Luciano Zardi, Ph.D.

(2) SPE Larry R. Helms, Ph.D.

(4) Giovanni Neri, Ph.D. and (5) Anthony Zelano.

Date of Interview: 02/15/2007.

Type: a) ☐ Telephonic b) ☐ Video Conference
c) ☒ Personal [copy given to: 1) ☒ applicant 2) ☒ applicant's representative]

Exhibit shown or demonstration conducted: d) ☒ Yes e) ☐ No.

If Yes, brief description: Power point slide demonstration.

Claim(s) discussed: 30-47, 53-55 and 57-63.


Identification of prior art discussed: See Continuation Sheet.

Agreement with respect to the claims f) ☐ was reached. g) ☐ was not reached. h) ☒ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.


ALANA M. HARRIS, PH.D.
PRIMARY EXAMINER
02/15/2007

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

Examiner's signature, if required

IDS reference number 23, submitted February 8, 2005); JP(A) H4-169195 (laid open June 17, 1992)/IDS reference number 24, submitted February 8, 2005); and U.S. Patent number 4,894,326 (issued January 16, 1990/IDS reference 1, submitted August 15, 2005)..

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Applicants and their representative presented information supporting their previous arguments that the prior art of record did not read on their claimed invention. After the presentation PTO personnel communicated the US patent rejection and the rejection based on JP(A) H2-76598 would fall. Applicants noted they would provide additional evidence supporting specific antibody OAL-TFN-01 disclosed in JP(A) H4-169195 does not bind directly to the ED-B oncofoetal domain of fibronectin in order to overcome the 102(b) rejection of record.